Foresee Pharmaceuticals Co., Ltd. (6576)

Overview

Foresee Pharmaceuticals Co., Ltd. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative drugs. With operations spanning the United States, China, and Europe, the company stands at the forefront of addressing some of the most challenging medical conditions. Established in 2013 and headquartered in Taipei, Taiwan, Foresee Pharmaceuticals employs a strategic approach to drug development, leveraging its expertise in stabilized injectable formulations to bring advanced therapeutic solutions to market. Their diverse pipeline includes treatments targeting a variety of significant health issues, from advanced stage cancers to neurological diseases and respiratory conditions.

Products and Services

Foresee Pharmaceuticals has developed a robust pipeline of products in various stages of clinical development, aimed at addressing unmet medical needs in oncology, neurology, respiratory diseases, and other therapeutic areas:

• FP-001: A stabilized injectable formulation that has completed Phase III clinical study for the treatment of advanced stage prostate cancer. This product represents a significant advancement in the therapeutic options available for prostate cancer patients.
• FP-004: Currently in the preclinical stage, FP-004 is being developed to treat opioid use disorder. This investigational drug aims to provide a new solution to the complex issue of addiction.
• FP-011 and FP-014: These long-acting sustained release dosage forms are being explored for the treatment of breast cancer and prostate cancer. Through sustained release technology, these products aim to provide improved efficacy and patient convenience.
• FP-016: A product in development for the treatment of neurological diseases. FP-016 shows promise in addressing the intricate challenges of managing and treating conditions affecting the nervous system.
• FP-020: This new chemical entity is aimed at treating sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema. FP-020 is in development to offer new hopes for patients suffering from these debilitating respiratory conditions.
• FP-025: A selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients. FP-025 demonstrates Foresee Pharmaceuticals' commitment to addressing respiratory diseases with novel therapeutic approaches.
• FP-045: A selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia. This product highlights the company’s endeavors in exploring treatments for rare diseases.
• FP-040: An ALDH2 activator targeting central nervous system diseases. FP-040 is under development to potentially offer new therapeutic options for managing diseases affecting the brain and nervous system.